Understanding how certain brain cells are affected by tau protein in Alzheimer's disease

Mechanisms of Susceptibility of Excitatory Neurons to Tau Pathology and Neurodegeneration in Alzheimer's disease

['FUNDING_R01'] · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · NIH-10764312

This study is looking into why certain brain cells in people with Alzheimer's disease are more likely to get damaged by a harmful protein, with the hope of finding new ways to protect these cells and improve treatments for patients.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (nih funded)
Locations1 site (NEW YORK, UNITED STATES)
Trial IDNIH-10764312 on ClinicalTrials.gov

What this research studies

This research investigates the reasons why specific excitatory neurons in the hippocampus are particularly vulnerable to tau protein accumulation and neurodegeneration in Alzheimer's disease. By using advanced techniques like single cell RNA sequencing and viral translating ribosome affinity purification, the study aims to identify the molecular pathways that lead to the damage of these neurons. The findings could help in understanding the progression of Alzheimer's and in finding new therapeutic targets to protect these vulnerable cells. Patients may benefit from insights that could lead to innovative treatments for Alzheimer's disease.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.

Not a fit: Patients with other forms of dementia unrelated to tau pathology may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic strategies that protect brain cells from damage in Alzheimer's disease.

How similar studies have performed: Previous research has shown promise in understanding tau pathology, but this approach using single cell techniques is relatively novel.

Where this research is happening

NEW YORK, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.